Biodesix Statistics
Share Statistics
Biodesix has 145.47M shares outstanding. The number of shares has increased by 50.06% in one year.
| Shares Outstanding | 145.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 74.02M |
| Failed to Deliver (FTD) Shares | 289 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 903.14K, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 903.14K |
| Short % of Shares Out | 0.62% |
| Short % of Float | 1.22% |
| Short Ratio (days to cover) | 1.35 |
Valuation Ratios
The PE ratio is -2.9 and the forward PE ratio is -6.36.
| PE Ratio | -2.9 |
| Forward PE | -6.36 |
| PS Ratio | 3.08 |
| Forward PS | 1.4 |
| PB Ratio | 32.99 |
| P/FCF Ratio | -3.29 |
| PEG Ratio | n/a |
Enterprise Valuation
Biodesix Inc. has an Enterprise Value (EV) of 185.39M.
| EV / Earnings | -3.56 |
| EV / Sales | 3.78 |
| EV / EBITDA | -5 |
| EV / EBIT | -4.48 |
| EV / FCF | -4.04 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 13.25.
| Current Ratio | 1.19 |
| Quick Ratio | 1.15 |
| Debt / Equity | 13.25 |
| Total Debt / Capitalization | 92.98 |
| Cash Flow / Debt | -0.38 |
| Interest Coverage | -4.34 |
Financial Efficiency
Return on equity (ROE) is -11.39% and return on capital (ROIC) is -63.34%.
| Return on Equity (ROE) | -11.39% |
| Return on Assets (ROA) | -0.53% |
| Return on Capital (ROIC) | -63.34% |
| Revenue Per Employee | 226.21K |
| Profits Per Employee | -240.30K |
| Employee Count | 217 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 9.29 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -39.47% in the last 52 weeks. The beta is 1.21, so Biodesix 's price volatility has been higher than the market average.
| Beta | 1.21 |
| 52-Week Price Change | -39.47% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 1.53 |
| Relative Strength Index (RSI) | 31.93 |
| Average Volume (20 Days) | 443.73K |
Income Statement
In the last 12 months, Biodesix had revenue of 49.09M and earned -52.15M in profits. Earnings per share was -0.64.
| Revenue | 49.09M |
| Gross Profit | 36.08M |
| Operating Income | -41.34M |
| Net Income | -52.15M |
| EBITDA | -37.10M |
| EBIT | -41.34M |
| Earnings Per Share (EPS) | -0.64 |
Balance Sheet
The company has 26.28M in cash and 60.69M in debt, giving a net cash position of -34.41M.
| Cash & Cash Equivalents | 26.28M |
| Total Debt | 60.69M |
| Net Cash | -34.41M |
| Retained Earnings | -419.57M |
| Total Assets | 102.74M |
| Working Capital | 31.05M |
Cash Flow
In the last 12 months, operating cash flow was -22.87M and capital expenditures -23.06M, giving a free cash flow of -45.93M.
| Operating Cash Flow | -22.87M |
| Capital Expenditures | -23.06M |
| Free Cash Flow | -45.93M |
| FCF Per Share | -0.56 |
Margins
Gross margin is 73.5%, with operating and profit margins of -84.22% and -106.23%.
| Gross Margin | 73.5% |
| Operating Margin | -84.22% |
| Pretax Margin | -106.23% |
| Profit Margin | -106.23% |
| EBITDA Margin | -75.59% |
| EBIT Margin | -84.22% |
| FCF Margin | -93.57% |
Dividends & Yields
BDSX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -55.65% |
| FCF Yield | -27.58% |
Analyst Forecast
The average price target for BDSX is $3, which is 160.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 160.9% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -4.62 |
| Piotroski F-Score | 3 |